STUDY QUESTION: Are the genetic variants FSHB −211 G>T (rs10835638), FSHR c.2039 A>G (Asn680Ser, rs6166) and FSHR −29 G>A (rs1394205) associated with serum FSH, LH and anti-Müllerian hormone (AMH) levels in reproductive age women, their menstrual cycle parameters and risk of infertility?
Introduction
The gonadotropins FSH and LH have a key role in modulating reproductive health in both sexes. Upon binding to the receptors expressed in testicular Sertoli and Leydig cells, gonadotropins stimulate spermatogenesis and androgen production in men. In women, dynamic expression of FSH and LH is mediated via ovarian receptors, regulating the cyclic recruitment of follicles, their development from early antral stage to maturation, and ovulation triggering.
A genetic contribution to normal and impaired reproductive endocrinology and fertility is well established in both sexes. In men, the strongest acknowledged genetic effect on circulating gonadotropin levels is conferred by FSHB −211 G>T (rs10835638), located in the promoter of the FSH beta-subunit encoding gene. FSHB −211 T-allele is associated with significantly lower serum FSH, decreased testicular volume and sperm count, increased LH and higher risk for idiopathic infertility (Grigorova et al., 2008 (Grigorova et al., , 2010 (Grigorova et al., , 2011 Ferlin et al., 2011; Laan et al., 2012; Tüttelmann et al., 2012) . In contrast, the data on the effect of the FSHB −211 G>T variant in women limited and published studies conflict in their observations and conclusions. No association between the FSHB −211 G>T and serum FSH was detected for healthy eumenorrheic Italian women (n = 193), recruited among patients attending the hospital for infertility diagnostic workup (La Marca et al., 2013) . A parallel study on German eumenorrheic women (n = 365), also recruited by the IVF unit, reported significantly higher FSH and LH, and reduced progesterone levels for the T-allele carriers (Schüring et al., 2013) . A genome-wide association study (GWAS) in 63,350 British women reported the association of the T-allele with longer menstrual cycles and later age at menopause and surprisingly, a protective effect against endometriosis (Ruth et al., 2016a) .
Two common polymorphisms in the FSH receptor gene, a missense variant FSHR c.2039 A>G (Asn680Ser, rs6166) and a promoter variant FSHR −29 G>A (rs1394205), have been investigated for their potential effect on female reproductive physiology nearly 20 years. The G-allele of the FSHR c.2039 A>G has been consistently associated with elevated basal level of FSH and increased gonadotropin requirements to achieve multiple follicular maturation in infertile patients undergoing IVF protocol (Perez Mayorga et al., 2000; Behre et al., 2005; Yao et al., 2011; Riccetti et al., 2017) . In addition, an association with longer menstrual cycle in normo-ovulatory women has been reported . Although the FSHR −29 G>A does not have a direct effect on serum FSH and LH levels (Wunsch et al., 2005) , the carriers of the A-allele have been reported to also require increased FSH in IVF procedures (Achrekar et al., 2009) . The results of published genetic association studies addressing the link between the FSHR c.2039 A>G and −29 G>A and infertility-related conditions such as polycystic ovary syndrome (PCOS), endometriosis, premature ovarian failure are inconclusive (Simoni and Casarini, 2014) .
Investigations on the effect of common FSHR variants in men have been limited and the reported effects appear to be moderate compared to the FSHB −211 G>T variant. For FSHR c.2039 A>G, a statistically significant association has been reported with total testes volume (Grigorova et al., 2013) and for FSHR −29 G>A with increased serum FSH (Grigorova et al., 2014; Tamburino et al., 2017) .
As there is an emerging evidence on the potential contribution of the FSHB −211 G>T in modulating not only male, but also female reproductive physiology, the current study aimed to clarify the published contradicting data of the primary effect of this genetic variant in reproductive age women. In order to position our study data in a wider context, we also analysed previously extensively investigated FSHR c.2039 A>G and FSHR −29 G>A polymorphisms. Genetic associations with female reproductive parameters were tested in two parallel study groups consisting of women of reproductive age-healthy women and women attending the fertility clinic due to the couple's infertility. As the major result, we report that the T-allele carriers of the FSHB −211 G>T had significantly and substantially elevated FSH and LH levels in both clinical study groups. The data also revealed that the carriers the of the FSHB −211 T-allele have increased predisposition to female idiopathic infertility. For the FSHR variants, the only detected association was between c.2039 A>G and serum FSH levels in eumenorrheic healthy women. We claim that the FSHB −211 G>T represents a major genetic modulator of female reproductive physiology and health, supported by the evidence from various published GWAS reports.
Materials and Methods

Ethic statement
The HAPPY PREGNANCY project was approved by the Ethics Committee of Human Research of the University Clinic of Tartu, Estonia (permissions no. 221/T-6, 17.12.2012) and it was carried out in compliance with the Helsinki Declaration. A written informed consent to participate in the study was obtained from each individual prior to recruitment.
Study subjects
Female participants were recruited at the Women's Clinic, Tartu University Hospital (TUH) March 2013-August 2015 in the framework of the HAPPY PREGNANCY research project. The project aims to test and evaluate the clinical relevance of serum markers and DNA polymorphisms in molecular diagnostics in reproductive medicine in men and women. The female arm of this observational prospective study focuses on both, pregnancy and fertility. The major group of recruited patients comprised pregnant women monitored from first antenatal visit to delivery (n = 2334). Additionally, non-pregnant women were recruited to analyse the genetic determinants of fertility (n = 358). All participants of this study were of white European ancestry and living in Estonia.
Individuals analysed in the current study represented two independent groups of non-pregnant unrelated women. The first subgroup comprised of eumenorrheic healthy women attending their gynaecologist for a routine check-up and without any known fertility problems (n = 169 and Table I ). Eligibility to be recruited to the study included regular menstrual cycles (21-35 days), no clinical signs of hyperandrogenemia, normal ultrasonography of uterus and ovaries (exclusion of uterine fibroids, malformations, endometrial polyps, polycystic ovaries, ovarian cysts), no fertility problems and no use of hormonal contraception at least one month before the recruitment. Women using non-hormonal contraceptive methods (copper intrauterine device, condom or spermicides) were eligible for recruitment.
The second group comprised of the female partners of couples referred to the infertility specialist at the IVF unit, Women's Clinic, TUH due to inability to conceive a child during the period of ≥12 months (all recruited patients, n = 189). The patients underwent detailed clinical assessment and determination of the causes for infertility. Tubal occlusion and endometriosis were diagnosed based on the laparoscopy examination. Endometrial factor was assigned as causative for infertility in cases where transvaginal ultrasound scan estimated endometrial thickness to be <6 mm in late proliferative phase, and for patients with an endometrial pathology (endometrial polyps, adhesions). Uterine fibroids or malformation were diagnosed using transvaginal ultrasound scan and/or hysteroscopy. Ovulatory disorders were assigned as the cause of infertility in women with irregular cycles or regular cycles exceeding physiological range (shorter than 21 and longer than 35 days). This group also contained cases of PCOS, diagnosed according to Rotterdam criteria (Rotterdam ESHRE/ ASRM-Sponsored PCOS Consensus Workshop Group, 2004) . In parallel, the male partners of infertile couples were examined at the Andrology Centre, TUH. Male factor was assigned as the cause of infertility if sperm parameters were repeatedly below the reference values (World Health Organization, 2010) . Clinical assessment of male partners is described in detail elsewhere (Punab et al., 2017) .
To diagnose the leading cause of a couples' infertility, an empirically developed hierarchy was applied, based on the severity of the clinical consequence on fertility potential. The diagnostic hierarchy was following (from more towards less severe effect; at authors' discretion) (i) tubal occlusion, (ii) ovulatory disorder, (iii) male factor, (iv) endometriosis, (v) endometrial factor and (vi) uterine fibroids or malformation. If none of the abovementioned causes were identified, the couples were classified as having idiopathic infertility (Supplementary Table SI) .
Among the recruited subjects, genomic DNA was available for all eumenorrheic healthy women (n = 169) and for 186 of the clinically phenotyped 189 female partners of infertile couples. The final number of analysed subjects was 355 (Table I) .
Clinical and hormonal assessment
Anthropometric data (height, weight) were recorded and the BMI was calculated as weight (kg)/height (m) 2 on the day of blood-draw. Additional complementary data on the reproductive history, previous clinical assessments, general health and life-style factors were retrieved from medical records or detailed self-reported questionnaires filled at the time of recruitment. For all participants of the study, venous blood was obtained during Days 2-6 of a spontaneous menstrual cycle. In cases of irregular cycle, the blood draw occurred after taking contraceptive pills to induce menstrual-like bleeding before the index cycle. Blood draw was followed by immediate separation of the serum for the measurements of FSH and LH concentrations. For the subsequent analysis of anti-Müllerian hormone (AMH), serum aliquots were frozen at −80°C. LH and FSH were measured using chemiluminescence immunoassay (Cobas 6000, Roche Diagnostics GmbH) at the United Laboratories, TUH according to manufacturer's instructions. The detection limit for both hormonal assay was 0.1 IU/L. The intra-and inter-assay CV-s were 2.6 and 3.6% for FSH, 0.7 and 1.6% for LH, respectively. Serum AMH concentration was measured in duplicate using a commercially available assay (AMH Gen II ELISA, Beckman Coulter, Inc., Brea, CA, USA) with a detection limit of 0.08 pg/ml, and intra-and inter-assay CV 2.9 and 3.6%, respectively.
Genotyping
The FSHB −211 G>T variant (rs10835638), the FSHR c.2039 A>G (Asn680Ser, rs6166) and the FSHR −29 G>A (rs1394205) were genotyped by PCR and allelic discrimination assay on the ABI PRISM 7900HT detection system (Applied Biosystems, Foster City, CA, USA) according to previously described approach (Grigorova et al., 2014) . Briefly, each PCR reaction (5 μl) contained 20 ng of genomic DNA, 1 μl 5 × HOT FIREPol ® Probe qPCR Mix Plus (ROX) (Solis BioDyne, Tartu, Estonia), 0.25 μl predesigned TaqMan SNP Genotyping Assay (ID:C_27829553_10 for rs10835638, C_2676874_10 for rs6166, C_426553_10 for rs1394205; Applied Biosystems, Foster City, CA, USA) and 3.75 μl ddH20. Default thermal cycling conditions were applied: 15 min at 95°C followed by 40 cycles of 15 s at 95°C, 1 min at 60°C and 2 min at 50°C. Results were analysed using the allelic discrimination endpoint analysis mode of the Sequence Detection software package, Version 2.4 (SDS 2.4). Quality control of genotyping was guaranteed by inclusion of previously sequenced positive control DNAs representing all alternative genotypes (major and minor homozygotes and heterozygotes) into each genotyping plate.
Data analysis
Summary estimates (mean ± standard deviation, median and 10-90th percentiles) and comparative statistics (Wilcoxon rank-sum test, chi-squared test) were calculated for general characteristics and main outcome variables using STATA software version 13.1 (StataCorp, TX, USA). Chisquared test was used to assess the concordance of genotype distributions with Hardy-Weinberg equilibrium in the full sample, as well as in the two subgroups (all tests: P ≥ 2.6 × 10 Menstrual cycle <25 days (n) 11 (7%) 12 (6%) 9.8 × 10
Duration of infertility (years) n.a. 4.74 ± 3.03 n.a. Groups were compared using chi-squared test for categorical and Wilcoxon rank-sum test for non-categorical variables. Statistically significant nominal P-values are highlighted in bold. c All measurements were taken on Days 2-6 of a menstrual cycle.
d Gravidity, total number of previous pregnancies; parity, total number of previous births; both gravidity and parity are calculated only among the women with previous pregnancies.
association with hormonal measurements (FSH, LH, LH/FSH and AMH) and length of menstrual cycle among healthy and infertile women. In association testing with age at menarche no covariates were included. Quantitative parameters with normal distribution among non-pregnant healthy women (LH and LH/FSH) were analysed using non-transformed data values ( Supplementary Fig. S1 ). The rest of the genetic association analyses were conducted using naturally log-transformed data to normalize the distribution of values. Even after the transformation the distribution of menstrual cycle length and age at menarche were not normalized, most probably due to a narrow range of data values in our small sample. After the linear regression analysis with ln-transformed data, the generated regression coefficient and standard error values were back-transformed to the original scale. The results of the two subgroups analysis were combined in a meta-analysis under fixed effects model. In the association testing of the addressed polymorphisms with menstrual cycle length, we excluded infertility cases with irregular menstrual cycles (n = 7). Correlation between hormonal parameters stratified according to the FSHB −211 G>T genotype was evaluated using Pearson's (r) correlation coefficient. All genetic association tests were implemented in PLINK software version 1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/) (Purcell et al., 2007) . The Bonferroni threshold to correct for multiple testing in linear regression analysis was estimated 0.05/60 = 8.3 × 10 −4 , considering the number of tested polymorphisms (three), the number of independent parameters (FSH, LH, AMH, age of menarche, menstrual cycle length), number of independent tested samples (two) and number of applied genetic models (additive, recessive). For meta-analysis, the Bonferroni threshold was estimated 0.05/30 = 1.7 × 10
, considering three tested polymorphisms, five independent parameters and two genetic models. In case-control analysis, genetic association of tested variants with infertility status was tested using Fisher's exact test (no covariates) and logistic regression adjusted by age, BMI and smoking status.
The proportion of total phenotypic variance of studied hormonal and menstrual function parameters explained by the FSHB −211 G>T, FSHR c.2039 A>G and FSHR −29 G>A genetic variants was estimated using the restricted maximum likelihood (REML) analysis implemented in Genomewide Complex Trait Analysis (GCTA) software (http://cnsgenomics. com/software/gcta/) (Yang et al., 2011) . Briefly, genetic relationship matrixes (GRMs) were calculated for each study sample to determine the genetic relationship between pairs of individuals. GRMs served as input into a REML analysis to produce estimates of the proportion of phenotypic variance (and respective standard errors) explained by the studied SNPs. REML analyses were adjusted for appropriate cofactors analogously to the individual SNP association tests.
Results
Clinical characteristics of the study groups
According to the main objectives of the study, two patient groups with different reproductive histories and clinical characteristics were analysed (Table I ). The healthy eumenorrheic non-pregnant women (n = 169; aged 27.6 ± 6.1 years) represented a suitable clinical group for genetic association analyses of quantitative clinical parameters, such as serum reproductive hormones. Comparative analysis of healthy eumenorrheic women and the female partners of infertile couples (n = 186; 32.4 ± 4.7 years) enabled to assess whether the carrier status of the tested genetic variants may predispose to infertility. As expected, the groups differed statistically for age and reproductive history, percentage of parous individuals and patients with irregular menstrual cycles. The women with previous gestations in the two clinical groups did not differ for gravidity, but there was a highly significant difference for the proportion of women with previous live births (healthy 87% versus infertile women 56%; P = 4.3 × 10 −7
) and pregnancy losses (16 versus 41%, respectively; P = 2.7 × 10 −4 ). Serum FSH and LH levels were increased among the infertility patients, reflecting their impaired reproductive physiology (P ≤ 1.8 × 10 −2 ; Table I ). In addition, women with infertility problems had higher BMI (24.4 ± 4.9 kg/m 2 versus 22.2 ± 3.2 kg/m 2 ; P = 5.5 × 10 −5 ) and higher percentage of smokers at the recruitment (20 versus 11%; 2.2 × 10 −2 ). There was no difference for the reported age at menarche, proportion of women with long (>33 days) and short (<25 days) menstrual cycles, serum AMH measurements and estimated LH/FSH ratio. For 95 (51.1%) of infertile couples a single cause of infertility was revealed, whereas 54 (29.0%) of cases were diagnosed with two to four known causal factors. The most prevalent cause for couple infertility was male factor (29.5%) followed by tubal occlusion (22.8%) and ovulatory disorder (13.8%) (Supplementary Table SI) . Idiopathic infertility was assigned to 36 couples (19.4%) with no identified causal factors.
T-allele of the FSHB 211 G>T variant is associated with significantly increased serum gonadotropin levels Due to substantial differences in reproductive physiology, genetic association testing between the FSHB −211 G>T variant (rs10835638) and hormonal parameters was carried out in the two study groups separately. Among the analysed eumenorrheic healthy women (n = 169), significantly higher circulating FSH and LH levels were measured in the subgroup of the carriers of the minor allele of FSHB −211 G>T (linear regression: T-allele effect for FSH 0.77 IU/L, P = 1.3 × 10 −2 ; for LH 1.34 IU/L, P = 3.1 × 10 −4 ; Table II ). Additionally, the TT-homozygous healthy women had elevated level of FSH (TT effect 2.45 IU/mL, P = 4.4 × 10 −2 ) and reduced level of serum AMH (TT effect −2.76 ng/mL,
; Table II ). Consistent genetic effects of the FSHB −211 G>T on serum FSH and LH were detected for the female partners of infertile couples (n = 186). Despite large inter-individual variation of both hormones among infertility patients, the T-allele was associated with increased circulating gonadotropins in the same order of magnitude as in healthy women (T-allele effect for FSH 0.90 IU/L, P = 7.0 × 10 −2 , and for LH 1.96 IU/L, P = 1.6 × 10 −4 ; Table II) . Notably, TThomozygous female partners of infertile couples exhibited an enhanced upregulation of LH production (TT-effect 4.70 IU/L, P = 2.8 × 10
−2
). Among infertility patients no association between the FSHB −211 G>T variant and AMH was detected.
As the major study outcome, meta-analysis further enhanced the statistical significance of the results obtained in the two independent study groups for the effect of T-allele on higher FSH (T-allele effect 0.80 IU/L, P = 1.2 × 10 −3
) and LH (1.58 IU/L, P = 1.8 × 10 −8 ; Table II ). Both of these associations remained significant after stringent Bonferroni correction for multiple testing. In addition, due to a more pronounced effect of the T-allele carrier status on circulating LH, meta-analysis also reached statistical significance for the increased LH/ FSH ratio among these women (P = 4.7 × 10
−3
). We carefully checked and excluded a possible impact of advanced age to explain the elevated FSH levels and LH among the T-allele carriers. No significant differences were detected for the correlation of FSH/AMH and age Linear regression adjusted by age, BMI and smoking status at the recruitment was applied to test the association with hormonal measurements and length of menstrual cycle. In the association testing menstrual cycle length, the cases with irregular menstrual cycle were excluded (n = 7). Association testing with age at menarche was conducted with no covariates. Quantitative parameters with normal distribution (serum LH and LH/FSH ratio in non-pregnant healthy women) were analysed using non-transformed data values. The rest of the association tests were conducted using naturally log-transformed data to normalize the distribution of values. After the linear regression analysis with ln-transformed data, the generated regression coefficient and standard error values were back-transformed to the original scale. Test results in the two subgroups were combined using meta-analysis under fixed effects model. Statistically significant nominal P-values are highlighted in bold. Significant results after Bonferroni correction for multiple testing (alpha = 0.05/60 tests = 8.3 × 10 −4 ) are indicated with (*). For the meta-analysis across the two study sample, Bonferroni significance level was estimated 0.05/30 tests = 1.7 × 10 −3
. among the subjects with alternative genotypes either among healthy eumenorrheic women or female partners of infertile couples ( Supplementary Fig. S2 ).The women in the TT-group were not significantly older compared to women in GG and GT group (Supplementary Table SII) . Although meta-analysis did not confirm the association of FSHB −211 G>T with serum AMH, we observed stronger correlation between the estimated LH/FSH ratio and circulating AMH among the T-allele carriers (r = 0.459, P = 3.0 × 10 −6 ) compared to GG-homozygotes (r = 0.171, P = 6.4 × 10 −3
; Supplementary  Fig. S3, Supplementary Table SIII) .
No significant association between FSHB -211 genotypes and age, BMI, length of menstrual cycle or age at menarche was detected (Table II) . However, we acknowledge that due to our small study sample and expected moderate effect sizes, the current study was underpowered (power estimates < 30%, data not shown) to assess the replication of previously reported associations with length of menstrual cycle or age at menarche (Ruth et al., 2016a) .
Analysed FSHR variants demonstrated restricted genetic associations with tested reproductive traits
The FSHR c.2039 A>G missense variant (Asn680Ser, rs6166) showed an association with FSH levels only among eumenorrheic healthy women (G-allele effect 0.56 IU/L, P = 4.6 × 10 −3 ; Supplementary   Table SIV) , whereas for the FSHR −29 G>A promoter polymorphism (rs1394205) a trend for association with menstrual cycle length was detected solely in infertility patients (A-allele effect −0.75 days, P = 2.8 × 10 −2 ; Supplementary Table SV) . These initial observations were restricted to only one study group and were not strengthened in meta-analysis. For these FSHR variants, no other genetic associations with the tested reproductive traits were detected. The analysis outcome was not affected by the distribution of age or BMI among the women with alternative genotypes (Supplementary Tables SVI  and SVII) .
FSHB −211 G>T is a major modulator of circulating gonadotropin levels in healthy and infertile women
The contribution of the tested variants to overall phenotypic variability in serum gonadotropin levels was estimated to evaluate their broader impact (Table III) . Among eumenorrheic healthy women, the FSHB −211 G>T (3.5% of total estimated parameter variance) and the FSHR c.2039 G>A (3.9%) variants exhibited a notable and almost equal contribution to the measured variability in the circulating FSH concentration. The estimated additive joint contribution reached as high as 7.4% of total serum FSH variance. The highest levels of FSH were measured for the FSHB −211 T-allele carriers (TT + GT group) with the FSHR c.2039 GG-genotype, whereas significantly lower hormone concentrations were detected for the women carrying the combination of the FSHB −211 GG-and FSHR c.2039 AA-genotypes (median 7.7 versus 5.8 IU/L, P = 9.6 × 10 −3 ; Table IV ). Among infertility patients, the genetic contribution to FSH levels was less pronounced, solely mediated by the FSHB −211 G>T genotype (1.6%; Table III) . Consistent with its role as a major driver of gonadotropin levels, only the FSHB −211 G>T genotype substantially modulated serum LH The effects of the tested genetic variants were estimated by using the restricted maximum likelihood analysis implemented in GCTA software (Yang et al., 2011 
Data are presented median (10-90th percentile) measured concentrations of serum FSH among the women carrying the respective the genotype combination. *Statistically significant difference in the distribution of serum FSH levels between the two subgroups (Wilcoxon rank-sum test, P-value = 9.6 × 10
−3
). levels among both eumenorrheic healthy (7.1% of total parameter variance) and infertile women (10.5%). The FSHR c.2039 G>A variant showed limited contribution to LH measurements only in eumenorrheic women (1.5%).
The estimated contribution of FSHR −29 G>A to gonadotropin levels (Table III) , and the impact of all three variants to serum AMH and menstrual function parameters was marginal or missing (data not shown).
The carrier status of the FSHB −211 T-allele predisposes to impaired female fertility potential
The FSHB −211 T-allele was enriched among infertility patients (allele frequency 16.7 versus 12.4% compared to controls; Table V) . Notably, the prevalence of T-allele among the women with idiopathic infertility (n = 36) was further increased and nearly doubled compared to controls (23.6 versus 12.4%; OR = 2.61 (95% CI: 1.27-5.36); P = 8.9 × 10 −3 ). There was a >3-fold excess of TT homozygotes among women with idiopathic infertility compared to controls (5.6 versus 1.8%, P = 3.5 × 10 −2
; Table V) . Among infertility patients compared to eumenorrheic healthy women also a trend for an increased proportion of the FSHR c.2039 major A-allele homozygotes was detected (Asn/Asn; 39.8 versus 32.5%; P < 0.1; Supplementary Table SVIII) . Interestingly, there was a significant enrichment of infertility patients compared to healthy women carrying the combination of the FSHB −211 T-allele and FSHR c.2039 Asn/Asn genotype (21/186 versus 6/ 169, 11.3 versus 3.6%; P = 8.1 × 10 −3 ; Supplementary Table SIX) .
Discussion
Our data demonstrated a major contribution of the FSHB −211 G>T variant (rs10835638) on serum gonadotropin level in reproductive age women, irrespective of their fertility status. In both study groups, healthy women and infertility patients, the FSHB −211 T-allele carriers were measured significantly higher serum FSH and LH concentrations (Table II) . Against expectations, the strongest genetic contribution of the FSHB −211 G>T variant was detected with serum LH (meta-analysis: T-allele effect 1.58 IU/L; P = 1.8 × 10 −8
), not with FSH as has been reported in all published studies in men (Grigorova et al., 2008 (Grigorova et al., , 2010 (Grigorova et al., , 2011 Ferlin et al., 2011; Tüttelmann et al., 2012) . Furthermore, on the contrary to the association of the T-allele with substantial negative effect on male serum FSH, the female T-allele carriers exhibited higher FSH (allelic effect 0.80 IU/L; P = 1.2 × 10
−3
). The results in Estonian women are fully consistent with a previous study on German IVF patients from University Clinics of Münster (Schüring et al., 2013) . This report also demonstrated the strongest effect on higher circulating LH (1.3 IU/L; P = 1.3 × 10 −4 ), followed by less pronounced positive effect on FSH (effect 0.99 IU/L; P = 4.6 × 10 −3 ). Furthermore, the estimated TT-homozygosity effects on serum gonadotropin levels in the two studies were nearly identical: LH 2.31 and 2.52 IU/L, FSH 2.04 and 2.05 IU/L for Estonian (Table II) and German women (Schüring et al., 2013) , respectively. Positive association between the FSHB −211 T-allele and circulating LH has been observed also in Danish peripubertal girls . Only a limited number of genome-wide association studies (GWAS) have targeted serum FSH and/or LH measurements and these studies have analysed either post-reproductive age women (Mbarek et al., 2016 , Ruth et al., 2016b or PCOS patients (Hayes et al., 2015 , Tian et al., 2016 . These GWAS-s have reported top-SNPs associated with either FSH or LH levels in the vicinity (12-37 kb) of the FSHB −211 G>T and showing linkage disequilibrium (r 2 > 0.67) with this variant (Table VI) . Intriguingly, the detected effects in peri-and postmenopausal women are rather in agreement with the published data on men reporting decreased FSH and increased LH among minor allele carriers (Grigorova et al., 2008 (Grigorova et al., , 2010 (Grigorova et al., , 2011 Tüttelmann et al., 2012) . We envision two alternative and possible complimentary scenarios that may explain the opposite effects of the FSHB −211 G>T variant in men and post-menopausal age females compared to women of childbearing age with cyclic changes of gonadotropins. First, in men and women after menopause both FSH and LH are constitutively produced by pituitary gonadotropes, while in reproductive age women these hormones are produced in dynamic manner during menstrual cycle. In vitro analysis of functional polymorphisms in human cell lines showed the FSHB −211 G>T promoter variant to cause 46-86% decreased transcriptional activation compared to wild-type G (Hoogendoorn et al., 2003) . Decreased basal transcription of the FSHB gene with the −211 G>T variant was confirmed in LβT2 murine gonadotrope cells, due to a reduced binding of the LHX3 transcription factor (Benson et al., 2013) . However, as menstruation and menstrual cycle is almost exclusively restricted to higher primates, studies in in vitro conditions and non-primate animal models do not allow to assess the sex-specific expressional differences in the human FSHB. Secondly, the observed opposite genetic effect of the FSHB −211 G>T promoter variant on serum FSH may arise due to the sex-specific Continued differences in the induction and/or compensatory feedback mechanisms (Schüring et al., 2013) . The cyclic changes of both gonadotropin levels in women are largely directed by the pulsatility of the GnRH (Bliss et al., 2010) . Unlike basal transcription, GnRH induction of FSHB expression is not altered by the −211 G>T promoter variant (Benson et al., 2013) . In the current study serum gonadotropin levels were measured during the days 2-6 of menstrual cycle characterized by relatively stable FSH level. This 'basal FSH' measurement is the most robust indicator of ovarian reserve. In case of reduced follicular reserve, a stronger GnRH-initiated gonadotropin stimulation is needed to ensure follicle growth and maturation before the ovulation. As the T-allele of FSHB −211 does not limit the expression of LHB, the production of LH rises to a higher level compared to FSH. Regarding the analysed FSHR polymorphisms, the only significant association was detected between the FSHR c.2039 G-allele carrier status and significantly higher circulating FSH levels among healthy eumenorrheic women (Supplementary Table SIV ). The FSHR c.2039 A>G had no effect on FSH levels in female partners of infertile couples and no conclusive effect was detected on serum LH in either of the study groups. The FSHR c.2039 A>G variant leads to Asp680Ser substitution in the intracellular domain of the FSH receptor, reducing its affinity to FSH and leading to higher circulating FSH levels to achieve follicular maturation (Perez Mayorga et al., 2000) . This feedback mechanism appears to function only in women with normal menstrual cycle.
The contribution of the FSHR −29 G>A promoter variant to serum gonadotropin levels in both, healthy and infertile women was negligible (Supplementary Table SV) . Overall, the analysis results of the FSHR variants in the current study were concordant with the majority of previously published data (Perez Mayorga et al., 2000; Yao et al., 2011; Simoni and Casarini, 2014; Riccetti et al., 2017) . Failure to detect an association of Day 3 FSH levels with either FSHR c.2039 A>G or FSHB −211 G>T in Italian premenopausal eumenorrheic women undergoing infertility workup may be possibly explained by undetermined cofactors (e.g. distinguishing explicitly female and male factor infertility) and/or limited sample size (n = 193, La Marca et al., 2013) .
As an additional insight, we estimated the contribution of the tested variants to the total phenotypic variance of measured gonadotropin concentrations. We admit that the accuracy of these estimates may be affected by small sample size in our analysis, as also reflected by high standard errors (Table III) . Nevertheless, the results provide supporting evidence for the main claims of the study. In healthy young women, the FSHB −211 G>T and FSHR c.2039 A>G together explained 7.4 and 8.6% of the measured FSH and LH levels, respectively (Table III) . Among infertile women only the FSHB −211 G>T appeared to act as a genetic determinant of gonadotropin concentrations with especially pronounced effect on LH (10.5% of the total variance). As a further benefit from this analysis, the estimated contribution of the analysed variants to circulating FSH levels in women were compared to the respective published data in men (Grigorova et al., 2014) . The three SNPs were reported to explain together 2.3% of the phenotypic variance in male serum FSH that is~3-fold lower estimate compared to the female data in the current study. Similar to the analysis outcome in women, the FSHB −211 G>T accounted for the largest proportion of the variance (1.4%) in young men as well as among infertility patients. Notably, male FSH levels were also modulated by the FSHR −29 G>A genotypes, whereas no strong effect was detected on male LH for any of the analysed variants. We propose that as in men, also in women the FSHB −211 G>T represents a major modulator of serum gonadotropin levels with strong and robust effects that are detectable even in patients with impaired reproductive physiology. No significant association was observed between any of the tested variants and serum AMH level (Table II, Supplementary Tables SIV and  SV) . This is in agreement with previous studies among infant girls in mini-puberty (Henriksen et al., 2016) , pre-and peripubertal girls (Hagen et al., 2013; Busch et al., 2016) and reproductive age women (La Marca et al., 2013) . In literature, the only significant association has been reported for the FSHR −29 G>A with higher serum level of AMH in 3-month-old girls (Henriksen et al., 2016) . AMH lacks cyclic variation and thus, represents a more convenient potential clinical marker for the assessment of ovarian reserve. The reduced level of serum AMH reflects a diminished pool of resting primordial follicles, but its value in assessing the natural fertility is still limited (Steiner et al., 2017) . A decreased LH/FSH ratio has been recently suggested as an alternative sign of diminished ovarian reserve even with normal 'basal FSH' . The two parameters, AMH and LH/FSH ratio have been shown to be significantly correlated across the entire timeframe of reproductive age (r = 0.35, P < 0.001) . In our study, the T-allele of the FSHB −211 G>T variant was significantly associated with increased LH/FSH ratio (P = 4.7 × 10
). This is consistent with association data reported on a 'proxy' SNP for the FSHB −211 G>T variant (Tian et al., 2016) (Table VI) . Interestingly, we observed a stronger significant positive correlation between serum LH/FSH ratio and AMH for the T-allele carriers compared to the GG-homozygotes (r = 0.46 versus 0.17; Supplementary Fig. S3 ; Supplementary Table SIII) . This may point to a more pronounced feedback mechanism in reproductive-age women with suboptimal production of FSH to guarantee sufficient follicular growth and maturation. Failure to maintain this feedback may confer a risk to infertility. Also, a lower number of live births among the infertile women with previous gestation(s) compared to eumenorrheic healthy women (56 versus 87%; Table I ) may reflect the diminished reproductive potential. However, much larger and focused studies are needed to accurately elucidate the effect of the FSHB −211 G>T genetic variants on female fertility.
We acknowledge that a small sample size and the design involving two clinical groups with different reproductive background may have limited the capacity to replicate the associations with the age at menarche and length of menstrual cycle reported in large population-based studies (Ruth et al., 2016a; Table VI) . Concordant with our study, also a recent investigation on 1432 healthy Danish girls detected no associations of the FSHB and FSHR variants with the age at menarche (Busch et al., 2017) that indicates the requirement of very large sample sets to reach the necessary statistical power. Consistent with the reported evidence in men the prevalence of the FSHB −211 T-allele was significantly overrepresented in female idiopathic infertility patients compared to controls (Table V, Supplementary Table SX and references therein). A trend for the association between the FSHB −211 T-allele carrier status and an increased risk for nulliparity was also observed among the UK Biobank participants in a large study for multiple reproductive traits (Ruth et al., 2016a) . The FSHR c.2039 A>G and FSHR −29 G>A variants have not been associated with either male or female fertility status (Supplementary Tables SVIII and  SX) . Interestingly, the carriers of the FSHB −211 T-allele combined with the FSHR c.2039 AA-genotype showed the most pronounced enrichment in infertile compared to healthy eumenorrheic women (P < 0.01). These patients exhibited also the highest serum FSH levels in the study group of infertile women (Table IV) . Future studies have to be targeted to uncover whether this observation represents a bychance finding due to small study groups or this genotype combination truly enhances risk to impaired female fertility.
As a final remark, we would like to highlight an abundance of GWAS peaks for several female reproductive traits that have been mapped to the vicinity of FSHB gene. In addition to the associations with serum gonadotropins and menstrual cycle parameters that were discussed above, the FSHB region also harbours GWAS hits for PCOS, endometriosis, parity and menopause (Table VI and references therein). In contrast, only one significant GWAS hit has been reported for the FSHR genic region, PCOS locus in Han Chinese (Shi et al., 2012) . The accumulating data suggests that the FSHB −211 G>T not only represents a key genetic modulator of female serum gonadotropin concentrations and reproductive physiology but is a possible contributing factor to other gynaecological diseases. In perspective, this genetic variant may have a diagnostic value in IVF clinics to detect female patients with genetically inherited altered circulating gonadotropin levels. As the FSHB −211 G>T variant is considered to have a pharmacogenetic potential in treating male infertility (Felice et al., 2011; Laan et al., 2012; Busch et al., 2015) , likewise it may contribute to a more personalized management scheme in female infertility.
Supplementary data
Supplementary data are available at Human Reproduction online.
